European Medicines Agency Validates Marketing Authorisation Application for Jemperli Plus Chemotherapy for the Treatment of DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
April 26, 2023
April 26, 2023
LONDON, England, April 26 -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on April 25, 2023:
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) validated the Company's Type II Variation for a potential new indication for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with a type of gynaecological cancer known as mismatch repair deficient (dMMR)/microsatellite instabilit . . .
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) validated the Company's Type II Variation for a potential new indication for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with a type of gynaecological cancer known as mismatch repair deficient (dMMR)/microsatellite instabilit . . .